Skip to Content
  • Autism

    A Mechanism for Thimerosal

    There’s some fresh news in the (quite possibly endless) debate about the vaccine preservative thimerosal. The Institute of Medicine is working on another report, due in several months. Their last report, in 2001, found no evidence to support a link, but didn’t dismiss the possibility, either. I’ve written about this topic before.… Read More
  • General Scientific News

    Nuclear Fusion, Wordsworth, German Cooking. The Usual.

    I’ve been remiss in not mentioning the new paper that’s coming out in Physical Review E from the group that’s reported possible sonochemical fusion. Their original paper from two years ago was the subject of one of my early blog posts (see the March 4 entry.) I’m very happy to hear that this work is… Read More
  • Infectious Diseases

    They Will Do Such Things. . .

    I see that Steven den Beste linked to me as a general source of med-chem info, which was good of him. He was discussing resistance in treatment of tuberculosis (on the way to a broader point about current events), so I thought I’d say a few words about antiinfective drugs. As I’ve mentioned in the… Read More
  • Drug Prices

    Welding the Steering Wheel

    Steve Postrel of SMU sent along an interesting comment (which he mentions he hasn’t fully worked through), one which takes us right back to drug pricing. Yep, to the cheers of some readers and the winces of others. He believes that my reply in the Feb. 22 “Reimportation’s Just the Beginning” post doesn’t quite add… Read More
  • Things I Won't Work With

    Things I Won’t Touch (1)

    I’m still working on my reply to the Matthew Holt article I mentioned yesterday, so I thought I’d do one of the awful reagents that I spoke of. I’ll kick things off with hydrogen fluoride. The chemically inclined members of my audience might be saying “Hold it! You said yesterday that you’d used hydrofluoric acid!̶… Read More
  • Blog Housekeeping

    Catching Up

    Little time for blogging the last day or two. I’ve been finishing up a paper to send to Bioorganic and Medicinal Chemistry Letters, the first one I’ve written in a while, and I’m checking over another paper that I’m a coauthor on. We’re deciding on where to send that one – the lead author suggested… Read More
  • Clinical Trials

    More From the Me-Too Front

    Some interesting mail has come in after last week’s post on comparative clinical trials. Reader C.B. that I spoke about here some time ago, but should have raised again: “It seems to me that something else is being left out: not all patients respond the same way to any particular drug. . . Suppose that… Read More
  • Clinical Trials

    Putting A Price on Proving It

    I’ve already had some reader mail (see here) about this article in today’s New York Times. It starts out looking like a real pharma-bashing exercise. Up to a point, it is – and up to a point, it’s deserved, too. But in the end it’s a more subtle piece, not that you’d guess that from… Read More
  • Cardiovascular Disease

    Ezetimibe, The Press, and More

    Credit where it’s due! Yesterday I mentioned the original chemist who started the ezetimibe story, but I should note that the drug itself was synthesized by another former colleague of mine, Stuart Rosenblum. He and a host of others developed a huge series of analogs, which built in more acitivity and greater in vivo stability. Read More
  • Cardiovascular Disease

    The Beginning? It’s Right Past the End. . .

    There’s a paper in the latest issue of Science from a team at Schering-Plough that may have tracked down how the company’s cholesterol absorption inhibitor (Zetia, ezetimibe) works. That news really takes me back. It’s been years now, so it won’t do any harm to mention that I used to work there. I had a… Read More